A Phase 1 interventional study of one dose of Influenza Vaccine and one dose of Influenza Vaccine in Influenza, sponsored by Beijing Chaoyang District Centre for Disease Control and Prevention. Status unknown. Open to participants aged 3 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2016-08-15.
Sponsored by Beijing Chaoyang District Centre for Disease Control and Prevention · Phase 1, Interventional, and Prevention
This study evaluates the safety of freeze-dried live attenuated influenza vaccine for intranasal administration in chinese adults aged 3 years and older.80 subjects will be divided into 2 groups, including 18 years and older and 3-17 years old. Subjects in each groups will randomly receive one dose of influenza vaccine or placebo in a 3:1 ratio.
2,265 studies on the registry are indexed under Influenza, Human; 173 are open to participants now.
This study's enrollment of 80 is below the median of 240 across 1,894 interventional studies indexed under Influenza, Human.
Browse Influenza, Human studies →Beijing Chaoyang District Centre for Disease Control and Prevention is the lead sponsor of 12 studies on the registry; none are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
One dose of Freeze-dried Live Attenuated Influenza Vaccine for Intranasal Administration in aged 18 years and older
Biological: one dose of Influenza Vaccine
One dose of Freeze-dried Live Attenuated Influenza Vaccine for Intranasal Administration in aged 3-17 years
Biological: one dose of Influenza Vaccine
placebo in 10 subjects aged 18 years and older on day 0
Biological: placebo
placebo in 10 subjects aged 3-17 years on day 0
Biological: placebo
Evaluate the rate of adverse reactions of Live Attenuated Influenza Vaccine for Intranasal Administration
Adverse reactions associated with vaccine will be observed in subjects after vaccination. Solicited local adverse events include Pain, Redness, Swelling, Induration, Rash, Pruritus at injection site. solicited general adverse events include Fever, Nausea, Vomiting, Diarrhea, Decreased appetite, Be agitated (irritability, abnormal crying), fatigue, allergy
Time frame: 3 months
No study locations are listed for this record.
This study is status unknown, as verified in Jan 2016. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Beijing Chaoyang District Centre for Disease Control and Prevention